/stocks — the workspaceLOADING
All NIKISEC filings, by type → · Earnings date & implied move · Search inside filings
Niki BioSolutions, Inc. (NIKI) is a measuring & controlling devices, nec company. Piotroski F-Score 3/7. Fundamentals from SEC filings; prices are end-of-day.
What’s behind NIKI’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
FY ending 2023-12-31 vs 2022-12-31.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from NIKI’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on NIKI plus an auto-SWOT — built from NIKI's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate NIKI using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has NIKI been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
Projected from NIKI's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentNIKI files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No lawmaker has disclosed a trade in NIKI under the STOCK Act.
No tracked institution reported a position in NIKI in the latest 13F round.
No open-market Form 4 buys or sells reported for NIKI in the last ~6 months.
Head office: London, United Kingdom · the company’s charter and its head office are in different countries.
A charter change was filed after this. An 8-K filed 2026-07-20reports an amendment to the company’s articles and a change to shareholder rights (Items 5.03 and 3.03). Reincorporations are reported that way, but so are routine changes such as a new series of preferred stock, and we have not read this one. If it moved the company, the next periodic report’s cover will show it.
Source: the cover page of Niki BioSolutions, Inc.’s 20-F filed 2026-03-27, on EDGAR. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works